View Transactions

Laidlaw Capital Markets

Laidlaw Capital Markets offers our clients alternatives to highly structured financings that often paralyze a company’s capital structure. WE ARE BRAND COGNIZANT and strive to perform outreach to a broad base of Healthcare and Technology fundamental investors. Our team has extensive experience in executing transactions for both debt and equity in the private and public markets.

Our objective is to perform in a way where we cultivate long term relationships with exciting and growth oriented companies. We “roll up our sleeves” and help our clients add top tier shareholders, increase their liquidity profile and get their story out in a meaningful and thoughtful way. As you will see in our Case Studies, we are able to leverage our diverse institutional and retail network of sophisticated investors to deliver superior results across a variety of deal structures.

The Laidlaw Capital Markets Team has collaborated with organizations in developing strategies and goals on an individual company basis as well as assisting them in navigating the path to achieve their desired results. We have a demonstrated track record of providing the best funding available for companies that have work to do prior to moving upstream. As your company continues to grow and mature, the Laidlaw Capital Markets Team stays with you and will make introductions to Healthcare Centric Funds and Investment Banks. We believe you will the find the Laidlaw Capital Markets Brand to be true partner in your growth.

We would happy to provide you with Management References at many of the companies we have assisted.

  • Initial Public Offering (IPO)
  • Follow-On Offering
  • Confidentially Marketed Public Offering (CMPO)
  • Registered Direct (RD)
  • PIPE Transaction
  • Private Placement
  • Block trade

All of our offerings

2022-12-19T12:23:58-05:00



NLS Pharmaceutics

Private Placement

$10,000,000 of up to $30,000,000

Investor: BVF Partners L.P.

Exclusive Introducing Broker
December 2022

2022-03-31T16:36:29-04:00



Soleno Therapeutics

Follow-On Offering
Common Stock
and Warrants

$15,000,000

Co-Manager
March 2022

2022-01-04T10:26:34-05:00

MEI
Pharma

PIPE Transaction
Follow-on Offering
Common Stock

$52,325,000

Financial Advisor
December 2021

2021-03-03T11:49:54-05:00


Evoke Pharma

Follow-On Offering
Common Stock
.

$14,375,000

Sole Book-Runner
January 2021

2021-03-03T11:48:30-05:00


Affimed

Follow-On Offering
Common Stock
.

$115,00,000

Co-Manager
January 2021

2020-06-25T12:26:45-04:00


Affimed

Follow-On Offering
Common Stock
.

$34,500,000

Co-Manager
November 2019

2018-05-14T13:55:01-04:00

MEI
Pharma

PIPE Transaction
Common Stock and Warrants
 

$75,000,000

Co-Placement Agent
May 2018

2018-05-17T20:34:24-04:00

Sesen
Bio

Registered Direct
Common Stock and
Warrants

$10,000,000

Exclusive Placement Agent
March 2018

2018-06-01T01:40:10-04:00


AIT Therapeutics

PIPE Transaction
Warrants
.

$9,820,154.54

Exclusive Placement Agent
February 2018

2018-05-04T14:37:33-04:00


Affimed

Follow-On Offering
Common Stock
 

$23,000,000

Financial Advisor
February 2018

2018-05-04T14:41:44-04:00

Cytori
Therapeutics

Rights Offering
Convertible Preferred
Stock and Warrants

$10,000,000

Financial Advisor
November 2017

2018-05-04T15:09:37-04:00

Onconova
Therapeutics

Registered Direct
Common Stock
 

$1,380,000

Sole Placement Agent
November 2017

2018-05-04T15:20:13-04:00

Repros
Therapeutics

Confidentially Marketed
Public Offering
Common Stock and Warrants

$3,000,000

Sole Book-Runner
May 2017

2018-05-04T15:27:52-04:00

Onconova
Therapeutics

Confidentially Marketed
Public Offering
Common Stock

$5,963,517

Sole Book Runner
April 2017

2018-05-04T15:34:41-04:00


BioSig Technologies

PIPE Transaction
Common Stocks
& Warrants

$4,349,954

Exclusive Placement Agent
March 2017

2018-05-04T15:28:33-04:00

Therapix
Biosciences

Initial Public Offering
Common Stock
 

$13,800,000

Sole Book Runner
March 2017

2018-05-04T15:28:47-04:00

Gemphire
 

PIPE Transaction
Common Stock & Warrants
 

$12,500,000

Co-Manager
March 2017

2018-05-04T15:32:10-04:00


AIT Therapeutics

PIPE Transaction,
Common Stock
and Warrants

$10,200,000

Placement Agent
March 2017

2018-05-04T15:34:50-04:00


Medovex Corporation

PIPE Transaction
Common Stock & Warrants
 

$3,022,000

Exclusive Placement Agent
February 2017

2018-05-04T15:57:47-04:00

Medovex
Corporation

PIPE Transaction
Common Stock
& Warrants

$1,398,033

Placement Agent
April 2016

2018-05-04T15:48:50-04:00


ImmunoCellular

Follow-On Offering
Common Stocks
& Warrants

$7,400,000

Lead Manager
August 2016

2018-05-04T15:45:14-04:00


Gemphire

Initial Public Offering
Common Stock
 

$30,000,000

Co-Manager
August 2016

2018-05-04T15:46:19-04:00


PhaseRx

Initial Public Offering
Common Stock
 

$18,500,000

Book Runner
May 2016